The mechanism of bile acid metabolism regulating lipid metabolism and inflammatory response in T2DM through the gut-liver axis

Yan Wang, Bohan Lv, Nannan Liu, Siyu Tao, Jinfang Dou, Jun Li, Ruxue Deng, Xiuyan Yang, Guangjian Jiang

Heliyon · 2024 · 18 citations · 33 references

DOIFull text

Open access

Concepts

TL;DR

The study aimed to investigate how alterations in gut microbiota and bile acid metabolism influence lipid homeostasis and inflammation in type 2 diabetes via the gut‑liver axis. Researchers performed 16S rRNA, metabolomic, and transcriptomic profiling of plasma and feces from T2DM patients and validated key findings in a diabetic mouse model. T2DM patients exhibited disrupted gut microbiota with increased bile‑acid‑producing bacteria, decreased short‑chain fatty acid producers, and altered bile‑acid and cholesterol metabolism pathways, leading to impaired intestinal barrier function, dysregulated lipid‑metabolism proteins (FGFR4, TRPM5, CYP27A1) and heightened inflammatory signaling (TLR6, MYD88, NF‑κB), thereby exacerbating glucolipid metabolic disorders and systemic inflammation.

Abstract

AimsThe main objective of this study was to analyze the changes of intestinal microflora and how bile acid metabolic pathways affect lipid metabolism in T2DM through the gut-liver axis.MethodsFirstly, 16S rRNA sequencing, metabolomics and transcriptomic sequencing were performed on plasma and feces of clinical subjects to determine the changes of intestinal flora and its metabolites. Finally, T2DM mice model was verified in vivo.ResultsT2DM patients have significant intestinal flora metabolism disorders. The differential fecal metabolites were mainly enriched in primary bile acid biosynthesis and cholesterol metabolism pathways in T2DM patients. After verification, the changes in gut microbiota and metabolites in T2DM patients (including up-regulated bacteria associated with BA metabolism, such as lactobacillus and bifidobacterial, and down-regulated bacteria capable of producing SCFAs such as Faecalibacterium, Bacteroides, Romboutsia and Roseburia); and the changes in the flora and metabolites that result in impairment of intestinal barrier function and changes of protein expression in the blood, intestine and liver of T2DM patients (including FGFR4↑, TRPM5↑ and CYP27A1↓, which are related to BA and lipid metabolism homeostasis, and TLR6↑, MYD88↑ and NF-κB↑, which are related to inflammatory response). These aspects together contribute to the development of further disorders of glucolipid metabolism and systemic inflammation in T2DM patients.ConclusionsChanges in intestinal flora and its metabolites may affect lipid metabolism and systemic inflammatory response in T2DM patients through the gut-liver axis mediated by bile acids.

References

33